STOCK TITAN
  1. Home
  2. News
  3. HRMY

Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PLYMOUTH MEETING, Pa., Jan. 5, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs will present a company update and host investor meetings at the upcoming 40th Annual J.P. Morgan Healthcare Conference.

  • 40th Annual J.P. Morgan Healthcare Conference
    Presentation: Thursday, January 13, 2022; 7:30AM ET
    1x1 Meetings: Monday, January 10, 2022-Thursday, January 13, 2022

A webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences 
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Media Contact: 
Nancy Leone 
215-891-6046 
nleone@harmonybiosciences.com 

Harmony Biosciences Investor Contact:
Patti Bank
ICR Westwicke
415-513-1284
ir@harmonybiosciences.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-40th-annual-jp-morgan-healthcare-conference-301454023.html

SOURCE Harmony Biosciences

Stock HRMY logo
Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

HRMY Rankings

#2005 Ranked by Market Cap
#4980 Ranked by Stock Gains
N/A Ranked by Dividends

HRMY Latest News

Apr 30, 2024
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
Apr 30, 2024
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Apr 16, 2024
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
Apr 11, 2024
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
Apr 3, 2024
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

HRMY Stock Data

1.75B
34.79M
19.38%
90.04%
11.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PLYMOUTH MEETING

About HRMY

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.